A novel study from the Institute of Environmental Medicine at Karolinska Institutet indicates that antibodies against a small lipid entity, phosphorylcholine (PC), can be associated with protection in inflammatory systemic diseases, including SLE and Sjögren’s syndrome. The results support evidence for a potential treatment by providing antibodies (anti-PC) to patients with these diseases or through